Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp (NYSE: NVRO), a pioneer in neuromodulation therapies for chronic pain management, provides this centralized hub for investors and healthcare professionals to access its latest developments. Track official press releases, clinical milestones, and business updates from the creator of the Senza spinal cord stimulation system.
This resource delivers timely updates on NVRO's FDA clearances, international expansions, and evidence-based innovations like its AI-enhanced HFX platform. Users will find disclosures covering product launches, financial results, and strategic partnerships that shape chronic pain treatment globally.
Key updates include advancements in 10 kHz therapy clinical applications, regulatory approvals across markets, and operational developments impacting patient access. Bookmark this page to stay informed about Nevro's progress in redefining neuromodulation standards through engineering and clinical excellence.
Nevro Corp. (NVRO) reported Q1 2021 revenue of $88.6 million, a 1% increase from the prior year. The net loss from operations was $22.5 million, with non-GAAP adjusted EBITDA of negative $6.6 million. The company updated its full-year revenue guidance to $440 million to $450 million, reflecting anticipated growth of 22% to 24% compared to 2020. Notable advancements include FDA approval for the Omnia upgrade and positive clinical trial results published in JAMA Neurology, indicating improved outcomes for patients.
Nevro Corp. (NYSE: NVRO), a leading medical device company specializing in chronic pain solutions, announced that its Chairman and CEO, D. Keith Grossman, will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 4:00 pm ET. The event will be accessible via a live webcast and archived recording on Nevro's website.
Nevro is known for its innovative Senza spinal cord stimulation system, which has shown positive outcomes, including opioid reduction in over 65% of patients in clinical studies. For more information, visit www.nevro.com.
Nevro Corp. (NYSE: NVRO) has launched its new HFX brand and updated website aimed at enhancing the experience for physicians and patients in chronic pain treatment. The HFX brand consolidates Nevro's offerings, including the U.S. launch of the Omnia upgrade powered by HFX Connect, which facilitates remote therapy optimization through dedicated HFX Coaches. This system leverages data from over 70,000 patient outcomes and includes features like remote diagnostics and real-time patient care tracking. The company anticipates expanding its HFX Connect upgrade to Australia and Europe shortly.
Nevro Corp. announced the appointment of Jon Shear as the new Vice President of Corporate Development, effective immediately. Shear, who has extensive experience in the medical technologies sector, will lead Nevro's strategic planning and business development initiatives. He previously founded Westward Medtech and held significant roles at Thoratec Corporation and St. Jude Medical. This leadership change may enhance Nevro's strategic alignment and long-term growth trajectory, critical for improving shareholder value.
On April 13, 2021, Nevro Corp. (NYSE: NVRO), a leader in innovative solutions for chronic pain treatment, announced that Keith Grossman, Chairman and CEO, will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 2:00 PM ET. A live webcast will be available on Nevro's website, alongside archived recordings for investors. Nevro is renowned for its Senza spinal cord stimulation systems, which utilize HF10 therapy to significantly reduce opioid dependency in patients.
Nevro Corp. (NYSE: NVRO) will report its financial results for Q1 2021 after the market closes on May 5, 2021. A conference call is scheduled for the same day at 1:30 PM PT to discuss the results. Investors can join the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally. Nevro focuses on innovative solutions for chronic pain, with its Senza spinal cord stimulation system showing the potential to reduce opioid use in over 65% of patients. For more information, visit www.nevro.com.
Nevro Corp. (NYSE: NVRO) announced the publication of the SENZA-PDN clinical trial results in JAMA Neurology. This trial evaluated the use of the Senza® System for treating chronic pain associated with Painful Diabetic Neuropathy (PDN), potentially becoming the first FDA-approved spinal cord stimulation (SCS) system specifically for PDN. The trial showed significant pain relief for 85% of patients using high-frequency (10 kHz) SCS compared to 5% in the control group. The FDA review is expected to take six months, with a potential launch planned for the second half of 2021.
Nevro Corp. (NYSE: NVRO) reported a fourth quarter 2020 revenue of $109.7 million, down 4% year-over-year, with a net loss from operations of $0.9 million. Worldwide revenue for 2020 reached $362.0 million, a 7% decrease from 2019. For 2021, the company expects revenue of $430 million to $450 million amid ongoing COVID-19 related challenges and plans to launch treatments for Painful Diabetic Neuropathy. Despite obstacles, Nevro anticipates a return to growth as pandemic conditions improve and elective procedures resume.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, announced that D. Keith Grossman, Chairman and CEO, will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:40 AM ET. A live webcast and archived recording of the presentation will be available on Nevro's website. The company is known for its innovative Senza spinal cord stimulation system, which has shown efficacy in reducing opioid dependency in chronic pain patients.
Nevro Corp. (NYSE: NVRO) announced that D. Keith Grossman, Chairman and CEO, will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25, 2021, at 1:30 PM ET / 10:30 AM PT. The event will be accessible via a live webcast on Nevro's website, where an archived recording will also be available.
Nevro, based in Redwood City, California, specializes in innovative solutions for chronic pain treatment, particularly through its proprietary HF10 therapy, proven to reduce or eliminate opioids in over 65% of patients.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
